Adifyline is the trade name for a cosmetic ingredient associated with acetyl hexapeptide-38. The active substance is a defined modified peptide, whereas the commercial ingredient described in the manufacturer’s documentation is a solution containing this peptide. The distinction is important because the evidence regarding the molecule, the delivered solution, and the finished cream address different scientific questions.[1][2]
Available evidence includes laboratory studies and cosmetic reports reported by the manufacturer. A recent case report identified in a targeted PubMed search also showed acetyl hexapeptide-38 as one of the components of the combined intervention. None of these types of evidence supports the claim that all products containing Adifyline cause permanent increases in tissue volume or restore lost facial muscle function. [3]
What is Adifyline? Names, synonyms and identity
The distinction between a trademark and the name of a component used in the INCI nomenclature is particularly important in cosmetology.
The trademark helps identify the supplier's commercial product, while the chemical name indicates the ingredient that may be present in multiple formulations.
The first name may refer to a specific carrier system, while the second describes a specific molecular unit.
None of them independently determines the amount of peptide that reaches the living tissues after topical application.
Adifyline can be found in descriptions regarding the fullness of the cheeks, facial contours, the appearance of breasts, and other cosmetic applications.
These are categories of declared use or marketing, and not separate, verified biological identities.
Cosmetic use related to external appearance should not be confused with the treatment of facial fat loss, facial nerve paralysis, or any other condition.
Even if the scientific report concerns the same molecule, the route of administration and the research population determine the significance of the evidence.
The FDA’s substance identification registry is useful for naming and sequencing purposes, but it is not a clinical trial database.
Similarly, the supplier's brochure helps to determine the composition of the commercial material, but the experimental results contained in it require independent evaluation.
Separating these source functions prevents the chemical identity registry from being mistakenly treated as confirmation of cosmetic efficacy.
Adifyline is associated with the documentation of the cosmetic ingredients Lipotec/Lubrizol.
Acetyl hexapeptide-38 is the name of the component that identifies its peptide portion.
The FDA’s substance identity registry assigns the name Adifyline to acetyl hexapeptide-38 and provides the sequence. Ac-Ser-Val-Val-Val-Arg-Thr. [1]
The prefix Ac stands for the acetyl group, and the six amino acid abbreviations describe the peptide chain.
Thanks to this, the name is more informative than the general term „cosmetic peptide”.
The identity register of the ingredient does not, however, specify the composition of each finished product that uses the trade name.
The manufacturer's brochure describes a solution containing butyl glycol, water, and acetyl hexapeptide-38.
It is therefore worth distinguishing between three concepts: acetyl hexapeptide-38 as the active molecule, the Adifyline peptide solution as the delivery ingredient, and the complete cream or serum sold to consumers.[2]
In scientific studies, it is necessary to indicate which level was examined.
The result obtained in cells exposed to the peptide cannot be automatically attributed to the cream.
Similarly, the result regarding one cream cannot be automatically transferred to another.
The name itself does not confirm comparable exposure, stability, or delivery of the component to the appropriate tissue.
How is Adifyline classified? Peptide, protein, mixture or other substance?
Hexamethylpyridin means six linked amino acid residues, and acetylation describes the chemical modification at the amino end.
This terminology distinguishes acetyl hexapeptide-38 from peptides that only have a similar numbering system.
The number 38 is part of the name of the component, and not an indication that the molecule contains 38 amino acids.
It should also not be interpreted as an indicator of the activity of the peptide or as evidence of kinship with other numbered peptides.
The carrier components of commercial material are important for cosmetic formulations, although they do not belong to the peptide sequence.
Butylene glycol and water can affect the dispersion of the ingredient and its incorporation into the finished formulation.
The peptide solution may be suitable for specific production conditions, but this does not prove that every resulting cream has equivalent stability or permeation ability.
The identity of the molecule and the action of the delivery system must be determined independently.
Distinguishing is also useful in SEO terminology.
Queries „Adifyline peptide”, „acetyl hexapeptide-38” and „Adifyline solution” may appear during the same search, but they relate to different topics.
Reliable educational content should not replace one concept with another without explanation.
The active substance is acetylated hexapeptide, that is, a chain containing six amino acid residues with an acetyl modification.
It is not a large protein or a naturally secreted human hormone.
The delivered cosmetic solution is a mixture containing a peptide and carrier components.[1][2]
Both descriptions can therefore be correct in different contexts.
Calling the active substance a peptide is justified chemically.
Defining the entire commercial solution as a single pure peptide would omit the other ingredients.
This is a common source of misunderstandings when the names of the ingredients become product names.
The classification should also be separated from the declaration of activity.
The very fact that the substance is a peptide does not confirm its penetration through intact skin, its reaching the subcutaneous tissue, a change in fat distribution, or the triggering of a clinically significant cosmetic effect.
These are empirical questions that require appropriate measurements.
Similarly, the presence in the FDA’s substance identification system does not mean that it can be approved as a drug.
The identity database clearly distinguishes the substance identifier from the regulatory assessment or permit.
The registration entry can help determine the meaning of the name, but it cannot be evidence of an approved therapeutic indication. [1]
The structure and composition of Adifyline – what has been established?
Record Ac-Ser-Val-Val-Val-Arg-Thr it describes the acetyl group at the end of N, followed by serine, three residues of valine, arginine and threonine.
This sequence is a chemical identifier, not a claim regarding a specific receptor, target tissue, or cellular transport mechanism.
Without direct experimental evidence of the presence of the acetyl group, it should not be considered as confirmation of effective penetration through intact skin.
It is especially easy to misinterpret the concentration level 0,05% provided for the delivered solution.
It describes the content of the peptide in the supplier's solution, and not the content of the peptide in each finished cosmetic product that uses that solution.
If the finished product indicates the percentage of the commercial complex, this value has a different denominator.
A scientifically justified comparison requires knowledge of the actual identity and concentration of the relevant substance, while taking into account that the concentration alone does not predict delivery or efficacy.
Analytical confirmation could include the sequence identity, content, purity, degradation products, and repeatability between batches.
These studies answer various questions.
The chromatographic purity result cannot by itself confirm the correct sequence.
However, sequence consistency does not prove stability after the peptide is added to the emulsion.
In scientific reporting, the documentation of the material being studied is actually more useful than a general statement that the formulation contains an active peptide.
The verified peptide sequence is Ac-Ser-Val-Val-Val-Arg-Thr.
It identifies the acetylated chain composed of six residues.
The sequence distinguishes this substance from other numbered cosmetic peptides whose similar names may conceal different molecular structures and research histories.[1]
With regard to the solution of the ingredient, the manufacturer's brochure specifies the content of acetyl hexapeptide-38 per 0,05%.
Therefore, information about the percentage of the Adifyline solution in the finished product should not be interpreted as the same percentage of pure peptide.
The denominator is crucial for correctly reading the concentration declaration. [2]
This is a general formulation guideline, not a recommendation regarding the preparation of the product.
The commercial complex can be introduced in a different formulation, but the amount of the complex is not equal to the amount of each of its components.
Without transparent documentation, two products that provide similar percentages may not deliver comparable amounts of active molecule.
The structural identity also differs from the analytical quality.
The sequence name does not confirm the actual content of the peptide, impurities, degradation, or stability during storage.
An appropriate assessment of the product would require chemical characterization and evidence that the formulation under investigation meets the requirements introduced on the market.
It is not necessary to assume a single universal molecular specification for all creams containing Adifyline.
The finished formulation includes its own emulsifiers, preservatives, moisturizing agents, and other ingredients.
They can affect tolerance and the appearance of the skin, even if they are not the subject of a peptide declaration.
Studies on Adifyline – evidence in humans, animals and in the laboratory
The evidence should be arranged according to the question it answers.
The provider’s cellular experiments primarily concern possible mechanisms.
Short cosmetic studies refer to visible or instrumentally measured surface changes.
The subsequent case report concerns a very specific clinical situation involving several interventions.
None of these sources replaces the randomized, independently repeated study of an isolated peptide administered locally, with anatomically verified results regarding the tissues.
The number of trials and the design of the study are not interchangeable concepts.
A small controlled experiment can more convincingly answer a narrow physiological question than a larger observation without control.
In turn, a well-designed short experiment cannot confirm the durability of the effect.
When evaluating Adifyline, it is necessary to check whether the comparator differed solely based on the presence of the peptide, whether the endpoints were determined beforehand, and whether the participants and the evaluators were blinded.
Results of laboratory tests
Preadipocytes are precursor cells that can undergo differentiation under appropriate conditions.
Measuring changes in gene expression during differentiation can help identify potential biological pathways.
The staining of intracellular lipids, on the other hand, may indicate altered lipid accumulation in the cells.
None of these endpoints directly determines the amount of newly formed mature fat tissue in a living human being.
The number of cells, their viability, the state of differentiation, and the lipid content can change independently.
The experimental environment also differs fundamentally from the use of local methods.
Cultured cells can be subjected to a known nominal concentration in the medium, while the intact epidermis forms a complex barrier.
Enzymatic degradation, binding to formulation components, diffusion, and local removal of the substance can alter exposure.
The observation of the concentration–response relationship in vitro Therefore, it should not be converted into the recommended cosmetic concentration or the prediction of visible results.
The manufacturer reports experiments on human preadipocytes in which the expression of genes related to adipogenesis was measured. PGC-1α and the accumulation of intracellular lipids during differentiation.
These are observations in vitro.
They provide justifications for further research, but do not confirm the delivery of the peptide to adipose tissue through intact skin or a lasting change in the anatomy of the human face.[2]
Cells maintained in differentiating media are directly exposed under controlled conditions.
The local product encounters a skin barrier, influenced by formulation, local metabolism, and uneven distribution.
The difference between these experimental conditions should be investigated, not ignored.
Human studies reported by the manufacturer
Two studies involving a total of 22 participants they should be treated as separate experiments, and not combined into a single study involving 44 people.
They evaluated different anatomical areas and used different observation periods: 14 days for cheeks and 56 days for breasts.
These details are important because the geometry of the skin, the subcutaneous tissue, the body's positioning, and the repeatability of the measurements vary depending on the location.
A change recorded in one area does not confirm a comparable change in another.
Comparisons of paired anatomical regions can control some of the participant's individual characteristics, but they introduce their own methodological questions.
Investigators must determine which side received the treatment, how the allocation was determined, and whether the assessment was blinded.
Repeated measurements of the surface require fixed reference points, arrangement and measurement conditions.
Without full statistical methods and uncertainty estimation, it is difficult to distinguish the reliable effect of the intervention from measurement variability.
Most importantly, the external contour is not a direct measure of the formation of new adipocytes.
Confirmation of the claim regarding the mass or distribution of fat would require imaging methods that allow the characterization of tissue compartments.
Therefore, the manufacturer's results regarding the surface area should be presented according to their actual meaning, and not as verified tissue regeneration.
The brochure describes the cheek examination in 22 women for 14 days and separate 56-day study in 22 women, In this study, an active cream was applied to one breast and a comparator product to the other.
Volume measurement methods were used.
The short brochure does not provide the detail of a full reviewed clinical report, and the results remain specific to the formulation and measurement method. [2]
Comparing even numbers is important because it can reduce some of the differences between the participants.
However, it does not eliminate the need for clear allocation, blinding, baseline measurements, repeatability, reporting of adverse events, and explanation of the analysis.
In the case of the cheek experiment, the short description does not clearly confirm the control of the base of the preparation.
The shape of the surface is also not a direct measure of tissue composition.
An apparent change in volume may require investigation of the effects of hydration, positioning, edema, measurement limits, and other factors.
Demonstrating the formation of new fat tissue would require evidence beyond the change in the external contour.
Published case report
Description of the case from 2026 constitutes a separate type of evidence and should not be combined with studies on the efficacy of cosmetics.
A project involving one patient does not allow the independent effects of self-induced changes, rehabilitation effects, participation in procedures, or other simultaneous factors to be separated from the possible effects of acetyl hexapeptide-38.
A detailed clinical narrative can be informative, but it does not allow an estimate of the average effect or the safety of the peptide in a specific population.
An additional limitation is the path of application and context.
Concomitant clinical intervention is not equivalent to the use of a consumer cream.
The result regarding facial features is not the same as the cosmetic endpoint regarding surface area volume.
The case description should be treated as a source of hypotheses.
It should not be used to advertise facial paralysis treatment or to suggest that a cosmetic product restores nerve function.
Report from 2026, Indexed in PubMed, acetyl hexapeptide-38 is described as an element of a combined procedural and biochemical intervention for chronic peripheral facial nerve paralysis.
It concerns one patient and several simultaneous elements.
The reported improvement does not allow determining the contribution of individual components nor confirming claims regarding the cosmetic product used topically.[3]
The case description can generate hypotheses, especially when it documents an unusual observation.
However, it does not provide control for the causal effect in a randomized study.
Invasive intervention combined with cosmetics is not equivalent to applying a cosmetic cream.
This article does not transform this report into a treatment technique.
Evidence from animal studies
The lack of directly verifiable animal evidence in this review should be presented narrowly.
This does not mean that all possible experiments on animals have been exhaustively ruled out.
It should also not be attributed to animal data regarding acetyl hexapeptide-38 regarding PGC-1α, fat tissue differentiation or unrelated peptide analogues without demonstrating that the same material was studied.
Distinction is important because mechanistic pathways can have different functions in different tissues.
The result in the laboratory model of adipocytes may not predict effects in the fat compartments of the face, the epidermis, or the subcutaneous tissue of a living organism.
The appropriate next step is to conduct studies specific to the particular molecule and formulation, rather than extrapolating from a broad biological pathway.
In this study, a direct animal experiment was not used to confirm the benefits of Adifyline.
This is a statement about the evidence selected and verified in the review, and not proof that there are no animal studies anywhere.
General studies of adipocytes or related pathways should not be presented as experiments involving exactly that peptide.
Action mechanisms studied in the case of Adifyline
PGC-1α participates in the transcriptional regulation of cellular metabolism, and its role may vary depending on the cell type and the biological state.
The observation of a marker change associated with PGC-1α does not prove that the local component is creating new fat cells.
The mechanistic interpretation should identify the exact test, time, exposure, and comparator group, rather than treating the name of the pathway as a complete explanation of the causal mechanisms.
The proposed local mechanism involves several unverified steps: peptide stability in the product, release from the carrier, passage through the skin barrier, penetration into appropriate cells, interaction with the biological pathway, and sustained change at the tissue level.
Each stage can limit the final effect.
A positive result from one stage does not mean that all subsequent ones will occur with significant intensity.
Even if future research showed changes in the fatty tissue, the cosmetic significance would require consideration of the distribution and symmetry.
Increased tissue volume is not automatically desirable in every place.
Changes in contour do not necessarily improve function or patient satisfaction reported.
It would be appropriate to assess the anatomical selectivity, reversibility, and long-term tissue effects, rather than assuming them.
The proposed mechanism focuses on signaling related to PGC-1α and the accumulation of lipids in differentiated cells.
PGC-1α is a transcriptional coactivator.
It should not be confused with a receptor PPARγ nor describe it simply as a switch to increase fat tissue.
The manufacturer’s experiments support a limited mechanistic hypothesis, rather than a full explanation of the effect of the local formulation on tissues.[2]
Several separate stages would require evidence.
The peptide would have to remain sufficiently intact in the formulation, reach the appropriate range, affect biological processes with effective exposure, and elicit a measurable result.
Demonstrating one step does not confirm the entire sequence.
Gene expression and tissue growth are also separate endpoints.
A change in the informational level of RNA does not guarantee an appropriate change in protein activity, cell number, or the permanent volume of tissue.
Even the increase in the staining of intracellular lipids does not in itself prove the formation of functional adipose tissue in humans.
The same caution applies to the location.
The overall cellular response does not confirm that the consumer product can selectively rebuild one facial region, leaving other areas unchanged.
Claims of precise local reconstruction require direct anatomical and clinical evidence.
The useful mechanistic section therefore explains what the researchers measured and identifies the missing cells.
It should not transform a likely path into a guaranteed cosmetic or therapeutic result.
Limitations of scientific evidence regarding Adifyline
Evidence should also be evaluated in terms of the completeness of the reporting.
Important details include the number of people included and who completed the study, baseline characteristics, randomization procedures, blinding of evaluators, measurement variability, pre-defined endpoints, adverse events, and how to proceed with missing observations.
The brochure may present selected results without providing information sufficient to independently reproduce the analysis.
This is a limitation of transparency, not evidence of the falsity of the observations.
The second problem is the attribution of the effect.
The finished cream can contain humectants, emollients, film-forming substances, and other ingredients that affect the visible contour or condition of the skin.
Even a measurable change in appearance does not identify acetyl hexapeptide-38 as the cause, unless the comparator isolates this component.
Repeating the study with the same formulation, followed by formulations developed independently, would help determine the repeatability and specificity of the effect.
Claims of durability, equivalence with injectable fillers, reconstruction of facial fat folds, or the treatment of neurological disorders essentially require different evidence than short cosmetic studies.
In public educational materials, uncertainty should be expressed directly, rather than being replaced by broad claims about proven increases in volume.
The evidence base is limited by the type of sources, small trials, short observation periods, and incomplete attribution of the effect.
Manufacturer data may be informative, but commercial summaries often omit the details needed to assess bias, uncertainty, and repeatability.
Independent testing of clearly defined finished products would increase certainty.
The central problem with endpoints is the difference between the contour and the tissue composition.
Measuring the volume of surface area can correctly describe the appearance, without indicating which tissue has changed.
The result should be called precisely, rather than being transformed into a broader claim about fat regeneration or permanent enlargement.
The second restriction concerns the transfer of results between characters.
The cell display, the use of a topical cream, and the procedure involving multiple materials are fundamentally different situations.
The result of one cannot confirm the others solely because the same peptide name appears.
Security evidence also requires a proportionate interpretation.
A small, short cosmetic study cannot rule out rare reactions or determine the long-term safety.
Tolerance depends on the full formulation, the application site, exposure, and individual characteristics, and not only on the peptide component.
Finally, the identified case description must remain the case description.
His clinical narrative does not support the approved treatment for facial paralysis and this conclusion is not drawn in this article.
The most justified position is that the defined cosmetic peptide has preliminary formulation and mechanistic evidence, but there are still significant gaps in independent clinical validation.
Frequently asked questions about Adifyline
1. Does Adifyline mean one defined substance?
It may refer to the defined peptide acetyl hexapeptide-38, but in commercial applications the name also includes a solution containing this substance.
The distinction should be explained before discussing the composition or concentration.
The finished cream constitutes an additional level of formulation and cannot be fully identified by its trade name alone.[1]
The claim regarding identity can be verified in a recognized chemical registry, whereas the claim regarding the product requires additional evidence at the formulation level.
The same trade name on two packaging does not constitute a test of analytical equivalence.
2. What do the available studies on Adifyline confirm?
They confirm preliminary laboratory observations and cosmetic measurements reported by the manufacturer for specific test materials.
The published case report with the associated intervention adds another, very limited type of evidence.
These sources do not confirm sustained tissue regeneration or consistent effects across all products.[2][3]
Evidence is strongest with respect to specific observations that have actually been measured.
It is not appropriate to extend their scope from the accumulation of lipids in cells to verified anatomical regeneration without indirect and clinical evidence.
3. Is acetyl hexapeptide-38 a peptide?
Yes. It is an acetylated peptide composed of six amino acid residues.
The chemical classification confirms its sequential identity.
However, this does not prove penetration, clinical efficacy, or the quality of the material delivered separately, which require other evidence.[1]
The acetylated modification and the six-membered chain define the peptide, not its bioavailability after topical application.
The chemical name answers the question of what the substance is, not what happens after its application.
4. Is the commercial solution a pure peptide?
No. The documented solution of the ingredient contains, in addition to the peptide, carrier substances.
Therefore, the percentage of the complex cannot be interpreted as the content of pure peptide.
Clear reporting of concentrations is necessary before comparing products or research materials.[2]
In concentration comparisons, the solution supplied by the supplier must be distinguished from the finished cosmetic product.
The carrier components belong to the supplied material and may differ between the finished products.
5. Does the FDA substance identifier mean that the ingredient is approved?
No. The identifier registers the identity of the substance and does not imply regulatory approval.
The FDA’s identification service clearly distinguishes between these issues.
It may support a claim regarding a name or classification, but does not justify a therapeutic claim.[1]
The registration of the name of the substance is separate from the assessment of the intended medical use.
It does not provide evidence of clinical safety, efficacy, or the approval of a specific cream.
6. Does increased gene expression indicate tissue growth?
No. Measurements of gene expression are biological observations at an earlier level of processes.
They do not measure directly the quantity, structure, or durability of the tissue.
The claim of growth requires evidence at the appropriate anatomical level, and not simply inference from a molecular marker.
The results of gene expression can vary without parallel changes in the amount of protein or the cellular phenotype.
Tissue growth is the endpoint of a higher level that requires direct measurement.
7. Does the accumulation of lipids in cells indicate the regeneration of facial fat?
No. The results of the cell culture do not confirm the delivery of substances or the remodeling of tissue within the face.
The culture conditions can directly expose the cells and promote differentiation in a manner that is not reproducible with local application.
The experiment supports a hypothesis that requires further research.
The intact skin barrier and the environment of living tissue are different from the culture of cells subjected to direct exposure.
The missing delivery stage is crucial for evaluating the cosmetic hypothesis.
8. Do the measurements of the surface area identify the tissue that has changed?
No. First and foremost, they are characterized by their external shape.
Moisture, placement, measurement limits, and other factors can affect the result.
Before assigning a change to a specific increase in the amount of adipose tissue, additional methods are needed.
The external geometry can change for reasons other than the enlargement of adipose tissue.
Claims regarding tissues under the surface should be supported by methods that allow the differentiation of tissue compartments.
9. Are cheek and breast examinations interchangeable?
No. They relate to different anatomical areas and research projects.
The local tissue structure and measurement conditions differ, therefore the results of one study cannot simply be transferred to another area.
The claims should remain linked to the place and formulation of the things actually assessed.
Even when using the same component, the anatomy of the cheeks and breasts is different, as are the exposure and measurement conditions.
The observed result must remain related to a specific experiment.
10. Does the short-term result confirm the durability?
No. Durability requires observation beyond the initial period, usually also after discontinuation of use.
The change measured during a short study does not indicate how long it lasts.
Therefore, durability remains an open question unless it has been directly measured.
Its determination would require measurements after a defined period of no further use.
Available short observations do not determine whether any change persists or reverses.
11. Is Adifyline equivalent to an injectable filler?
No. The cosmetic ingredient and the injectable filler are different products, with different mechanisms and evidentiary requirements.
A common marketing reference to volume does not imply equivalence of effects or risk.
Comparative claims require direct, appropriate research.
Cosmetic fillers and peptides have different formulations, delivery methods, and risk profiles.
The terminology regarding volume should not obscure these differences.
12. Does the case report of facial paralysis prove that the peptide treats paralysis?
No. The report concerned one patient receiving a combined intervention.
It does not allow the participation of the peptide to be isolated or alternative explanations for the observations to be ruled out.
It is evidence that generates hypotheses, not confirmation of established treatment.[3]
An uncontrolled case description does not allow the influence of the peptide to be separated from the other elements of the intervention.
It also does not allow for an estimate of the typical effects of the treatment in other patients.
13. Can the case study support claims regarding the topical cream?
No, when the intervention and the route of application differ significantly.
The presence of the same named component does not eliminate differences in formulation, exposure, and co-interventions.
The local product requires evidence that corresponds to the conditions of its own use. [3]
The path of intervention is part of the causal question.
Evidence from the combined procedure cannot confirm the action of the topical preparation simply because one named ingredient is common.
14. Does a higher percentage of the complex guarantee a greater effect?
No. The concentration alone does not determine delivery, activity, or tolerance.
The amount of active peptide, the stability of the formulation, and the biological response are also important.
The dose-response relationship must be demonstrated, not assumed based on the label.
The curve of the response to the amount of the component cannot be inferred from the marketing percentage.
Higher concentrations can also change the stability or irritant potential without improving efficacy.
15. Are all creams containing Adifyline equivalent?
No. Their bases, additional ingredients, stability, and exposure may vary.
Even if the same solution of the ingredient is used, the finished formulations may behave differently.
Therefore, evidence regarding a specific product is more informative than the name of the ingredient itself.
The characteristics of the finished product, such as pH, preservation, packaging, and other ingredients, can affect the performance.
The identical nomenclature of the ingredients does not confirm equivalent exposure.
16. What would stronger scientific evidence look like?
They would include independently evaluated studies controlled with a clearly defined formulation, previously established endpoints, full safety reporting, and appropriate long-term follow-up.
The anatomical claims would require measurements of the tissue composition.
The repeatability of the results between studies would increase the certainty over a single promotional summary.
The convincing program would include a well-characterized formulation of the studied substance and a comparator, repeatable measurements, and observation.
Anatomical claims require direct anatomical evidence.
17. What is the most accurate short description of Adifyline?
Adifyline is a cosmetic peptide ingredient associated with acetyl hexapeptide-38, usually supplied as a formulation solution.
The studies are preliminary and do not confirm broad therapeutic claims or a sustained increase in volume.
The description preserves both the verified identity and the limitations of the evidence.[1]
The concise characterization should maintain molecular specificity and evidence limitations.
Neither the substance identifier nor the supplier's brochure confirm the approved therapeutic use.
Interpretation of claims regarding the increase in the volume and quality of cosmetic research
The word „volume” can describe different measurements.
Three-dimensional surface imaging measures the contour.
Ultrasound or other imaging of tissues can help characterize structures located deeper.
Cellular tests measure responses in a controlled biological system.
These methods should not be presented as alternatives.
The percentage change in surface area, if reported, requires a clearly defined area of interest, a baseline value, a comparator, a measurement error, and statistical analysis before it can be properly interpreted.
Distinguishing between the ingredient and the finished product is equally important.
The moisturizing properties of the cream can change the appearance of the skin without the need for a permanent change in the deeper layers of tissue.
In turn, an experiment on isolated cells can reveal a molecular response without confirming that the same molecule reaches them through the skin.
A rigorous research program would combine chemical characterization, delivery measurements, tissue-specific results, and observations of clinical significance.
Independent replication of studies is valuable because it verifies whether the results depend on a single laboratory, supplier, formulation, or measurement technique.
Repeating small studies with the same limitations does not have to remove uncertainty.
Better evidence would include previously defined key endpoints, appropriate controls, transparent analysis, and the publication of both positive and negative results.
Research priorities and unresolved questions
The central research priority is the exposure after topical application: does acetyl hexapeptide-38 remain intact, cross the appropriate barriers and reach the target cell compartment at biologically relevant concentrations.
Without such evidence, the results in vitro They remain mechanistic observations, not confirmation of a local tissue effect.
Specific studies would be necessary for the formulations, as different cosmetic carriers may behave differently.
The second priority is the specificity of the endpoints.
Future controlled studies could distinguish transient changes in the surface from permanent changes in deeper tissues using standardized imaging and clearly defined anatomical regions.
The studies should report the magnitude and variability of changes, the responses of individual participants, cases of discontinuation of participation, and follow-up after the end of use.
These methods would help determine whether the observed effect is repeatable, significant, and lasting.
The third priority concerns tolerance and safety under realistic conditions of use.
Small cosmetic experiments have limited ability to detect rare reactions and long-term results.
Any proposed medical application would require its own pre-clinical and clinical development program, rather than relying on the documentation of the cosmetic ingredient or a single case report of a combined intervention.
Educational, medical and regulatory reservations
The article is of a scientific and educational nature. It does not constitute medical advice, diagnosis, treatment recommendations, or instructions for preparing, administering, injecting, or otherwise using acetyl hexapeptide-38. The laboratory results and studies reported by the manufacturer should not be interpreted as evidence that the cosmetic product rebuilds fat tissue, permanently enlarges tissues, or cures diseases.
Adifyline is the trade name associated with a solution containing a peptide. The FDA identifier does not mean approval of cosmetic claims or authorization for the treatment of diseases. Regulatory requirements depend on the jurisdiction, formulation, claimed action, and intended use. Individuals with facial asymmetry, tissue loss, facial nerve paralysis, or other medical conditions should consult a qualified specialist.
Conclusions
The active peptide Adifyline has a defined chemical identity, but its commercial solution and finished products require separate description.
Laboratory results, small studies by the manufacturer, and a case report of the combined intervention answer various questions.
Evidence should be presented with respect for these distinctions, especially when claims go beyond cosmetic appearance and concern tissue regeneration or the treatment of diseases.
References
- U.S. Food and Drug Administration. (n.d.). Acetyl hexapeptide-38 (UNII XUJ27AR5LA) [Record of substance identity]. https://precision.fda.gov/uniisearch/srs/unii/xuj27ar5la
- The Lubrizol Corporation. (2016). Adifyline peptide: Perfect curves against gravity (Ed. 16B) [Manufacturer brochure]. https://daltosur.com/media/documents/adifyline-peptidebrochure.pdf
- Calfin, H., Riquelme, V., Velazco, G., Sequera, M., & Castro, C. (2026). Facial adipostructuring with biochemical modulation in chronic peripheral facial paralysis: a case report. Cureus, 18(6), e111350. https://doi.org/10.7759/cureus.111350